ストックスクリーナーアプリを入手
2.77
4.48%
-0.13
アフターアワーズ：
2.82
0.05
+1.81%
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail
CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network
CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView
Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News
CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan
Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan
Cellectar Biosciences, Inc. Advances Iopofosine I-131 Submission for Waldenström Macroglobulinemia and Initiates Phase 1b Study of CLR 125 in Triple Negative Breast Cancer - Quiver Quantitative
Cancer-drug firm gets FDA breakthrough tag, yet lost $21.8M in 2025 - Stock Titan
Insights into Cellectar Biosciences's Upcoming Earnings - Benzinga
Cellectar Biosciences Inc expected to post a loss of $2.02 a shareEarnings Preview - TradingView
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Aug Mood: Is Cellectar Biosciences Inc currently under institutional pressureJuly 2025 Retail & Stepwise Swing Trade Plans - baoquankhu1.vn
CLRB SEC FilingsCellectar Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analyst Upgrade: Will Cellectar Biosciences Inc benefit from rising consumer demandMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
CLRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Nasdaq Moves: How cyclical is Cellectar Biosciences Incs revenue streamMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - Investing News Network
CLRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Bear: What drives Cellectar Biosciences Inc.’s stock priceQuarterly Profit Review & AI Forecasted Entry and Exit Points - mfd.ru
Gap Down: What are Cellectar Biosciences Incs growth leversJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition - AOL.com
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cellectar Biosciences Expands Global Intellectual Property Estate - Investing News Network
Cellectar Biosciences Expands Global Intellectual Property Portfolio Ahead of Iopofosine I 131 Marketing Approval for Waldenström Macroglobulinemia - Quiver Quantitative
Will Cellectar Biosciences Inc. benefit from rising consumer demandCEO Change & Comprehensive Market Scan Insights - mfd.ru
Analysis Recap: Whats the fair value of Cellectar Biosciences Inc stockQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Bleichroeder group discloses 4.61% CLRB stake in amended ownership filing - Stock Titan
Is Cellectar Biosciences Inc. stock risky to hold now2025 Top Gainers & Advanced Swing Trade Entry Alerts - mfd.ru
How cyclical is Cellectar Biosciences Inc.’s revenue streamEarnings Miss & Verified Technical Signals - mfd.ru
Is Cellectar Biosciences Inc. a top pick in the sector2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru
Will Cellectar Biosciences Inc. stock reach all time highs in 2025 - mfd.ru
Rosalind group discloses 5.5% Cellectar (CLRB) stake with conversion caps - Stock Titan
Can Cellectar Biosciences Inc weather a recession2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Can Cellectar Biosciences Inc. disrupt its industryQuarterly Growth Report & Real-Time Volume Spike Alerts - mfd.ru
Risk Report: Is BioLineRx Ltd Depositary Receipt a top pick in the sectorInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Weekly Trades: Is Cellectar Biosciences Inc a top pick in the sector - baoquankhu1.vn
What’s the fair value of Cellectar Biosciences Inc. stock - mfd.ru
Stock Analysis: What is the Moat Score of NAMIJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Cellectar Biosciences Inc disrupt its industryJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
What catalysts could drive Cellectar Biosciences Inc. stock higherMarket Insider Reports & Low Risk Trading Ideas - Bollywood Helpline
Is Cellectar Biosciences Inc currently under institutional pressure2025 Earnings Impact & High Return Trade Guides - baoquankhu1.vn
Fundamentals Check: How volatile is Cellectar Biosciences Inc stockWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ideas Watch: How cyclical is Cellectar Biosciences Incs revenue streamWeekly Stock Analysis & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Technicals: Does Cellectar Biosciences Inc have a sustainable dividendQuarterly Earnings Report & Smart Allocation Stock Reports - baoquankhu1.vn
CLRB: Strong clinical data and regulatory momentum drive expansion in targeted oncology programs - TradingView
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - marketscreener.com
Cellectar Advances CLR 125 Into Early Breast Cancer Trial, Adding Depth to Its Radiotherapy Pipeline - TipRanks
Cellectar Biosciences to highlight strategic initiatives for 2026 - marketscreener.com
Cellectar Biosciences Outlines 2026 Strategic Plan and Regulatory Milestones for Iopofosine I 131 and CLR 125 at Biotech Showcase - Quiver Quantitative
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase ... - bdtonline.com
Cellectar Biosciences to Highlight Strategic Initiatives - GlobeNewswire
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):